- Todos > Medicine Information and Evidence for Policy > Medicines Policy
- Todos > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Palabras clave > clinical trials novel product - public health emergency
- Palabras clave > Emergency Use Assessment and Listing Procedure (EUAL)
- Palabras clave > epidemic preparedness - development and production of health technologies
- Palabras clave > financing for R&D - preparedness and response to emergencies (emerging infectious pathogens)
- Palabras clave > pharmaceutical research - priorities
- Palabras clave > research and development
- Palabras clave > research and development - priority infectious disease
(2016; 36 pages)
On 21 July 2016, a 2nd Technical Workshop on R&D platform technologies was convened at the World Health Organization (WHO) headquarters in Geneva with the goal of presenting the 6 most meritorious proposals emerging from the WHO public consultation on platform technologies, for consideration by interested WHO Member States and relevant R&D funders.
Launched by WHO in October 2015, this public consultation is one activity within the WHO Research and Development (R&D) Blueprint, a global effort pioneered by WHO to increase R&D preparedness for future epidemics.
The focus of this 2nd technical workshop was on having concise technical presentations of the six final proposals while fostering an enabling environment for bilateral and/or multilateral discussions around potential future collaborations and/or support, between proponents and interested WHO members states and other organizations which fund R&D.
After a brief overview of the WHO R&D Blueprint, information was provided on the Coalition for Epidemic Preparedness Innovation (CEPI); and following a summary of the public consultation process since its launch, the six finalists (3 vaccines, 1 diagnostics, 1 immunotherapy, 1 covering all product streams) presented their ideas in open sessions.
The topics covered during the workshop included:
The principle of “no profit/ no loss” and social responsibility and the subsequent approach of offering products at no cost to populations in need was agreed to be guiding the philosophy of the majority of the presenting groups, with the exception of those entities which, due to their structure and turnover, pointed to the fact that they needed to balance this principle with the requirement to be a sustainable and profitable business. As a follow-up to the process, WHO proactively engaged potential funders in order to advance funding for the most promising ideas.